Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06839469 · ClinicalTrials.gov registry record
Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders
A clinical trial of Spinal Muscular Atrophy Type 3 and Duchenne Muscular Dystrophy (DMD), sponsored by Columbia University.
- Recruiting
- Registry status
- 106
- Enrollment target
- 3
- Study locations
NCT06839469: Recruiting study of Spinal Muscular Atrophy Type 3 and Duchenne Muscular Dystrophy (DMD), sponsored by Columbia University.
NCT06839469 is a study of Spinal Muscular Atrophy Type 3 and Duchenne Muscular Dystrophy (DMD) that is actively recruiting participants, run by Columbia University. The registered enrollment target is 106 participants, above the 83-participant average among 9 other Spinal Muscular Atrophy Type 3 trials with a reported enrollment target (28% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06839469, a study of Spinal Muscular Atrophy Type 3 and Duchenne Muscular Dystrophy (DMD), is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- 106 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research is (1) to identify disease specific walking-related digital biomarkers of disease severity, and (2) monitor longitudinal changes in natural environments, for extended periods of time, in DMD and SMA.
Primary Outcome
Participants will complete the six minute walk test in a corridor which includes the instrumented walkway, while wearing the insoles. This is to measure spatial parameters, kinetic parameters, temporal parameters, and metrics of cumulative activity in order to compare against the gold standard instrumented walkway. The six minute walk test is an objective evaluation of functional exercise capacity, and measures the maximum distance a person can walk in six minutes over a 25 meter course.
Conditions Studied
Study Locations (3)
California
- Stanford University - Palo Alto
Massachusetts
- Boston Children's Hospital - Boston
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2028-04-01 |
What NCT06839469 shows while recruiting
NCT06839469 is an observational study that tracks outcomes without assigning an intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, above the 83-participant average among 9 other Spinal Muscular Atrophy Type 3 trials with a reported enrollment target (28% higher).
The record links to 2 conditions, with Spinal Muscular Atrophy Type 3 appearing as the primary indexed condition, and to 0 interventions.
NCT06839469 reports a single indexed study location in California, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT06839469 about?
NCT06839469 is a clinical study titled "Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders". The purpose of this research is (1) to identify disease specific walking-related digital biomarkers of disease severity, and (2) monitor longitudinal changes in natural environments, for extended periods of time, in DMD and SMA.
What is the current status of trial NCT06839469?
This trial is currently recruiting. The enrollment target is 106 participants. The study started on 2024-05-01. Estimated completion is 2028-04-01.
What conditions does trial NCT06839469 study?
This clinical trial studies the following conditions: Spinal Muscular Atrophy Type 3, Duchenne Muscular Dystrophy (DMD).
Who is sponsoring clinical trial NCT06839469?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06839469 being conducted?
This trial has 3 study locations across California, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Muscular Atrophy Type 3
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06839469's enrollment target sits among peer trials
106 4th of 9 higher than 6 of 9 other Spinal Muscular Atrophy Type 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Spinal Muscular Atrophy Type 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gait and Bone Health in SMA
RECRUITING
-
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
RECRUITING · Phase 2
-
Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb
ACTIVE NOT RECRUITING · NA
-
Spinraza in Adult Spinal Muscular Atrophy
ACTIVE NOT RECRUITING
-
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
ACTIVE NOT RECRUITING · Phase 3
-
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI